Juliana Pereira
Overview
Explore the profile of Juliana Pereira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
922
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malpica L, Idrobo H, Pavlovsky A, Miranda E, Castro D, Beltran B, et al.
Lancet Haematol
. 2025 Mar;
PMID: 40056928
Background: Peripheral T-cell lymphomas represent a rare and heterogeneous group of mature T-cell neoplasms characterised by aggressive behavior. Previous studies evaluating peripheral T-cell lymphoma epidemiology across Latin America have been...
2.
Valente M, Sanches J, Nukui Y, Cury-Martins J, Souza B, Pereira J, et al.
Front Med (Lausanne)
. 2025 Feb;
12:1505865.
PMID: 39991055
Introduction: Human T-lymphotropic virus type-1 (HTLV-1) is endemic in some countries, including Brazil. HTLV-1 is the etiological agent of adult T-cell leukemia-lymphoma (ATLL), a rare and aggressive CD4+ T-lymphocyte malignancy....
3.
Nogueira D, Lage L, Reichert C, Culler H, de Freitas F, Mendes J, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682103
Clinical staging (CS) and tumor burden (TB) play a significant role in FL prognosis and direct its up-front therapy. The aim of this study is to report prognostic factors and...
4.
Lasrado N, Rowe M, McMahan K, Hachmann N, Miller J, Jacob-Dolan C, et al.
Sci Transl Med
. 2024 Oct;
16(770):eadp8920.
PMID: 39441905
Current COVID-19 vaccines provide robust protection against severe disease but minimal protection against acquisition of infection. Intramuscularly administered COVID-19 vaccines induce robust serum neutralizing antibodies (NAbs), but their ability to...
5.
Reis A, Maximino J, Lage L, Gomes H, Pereira J, Brofman P, et al.
Stem Cell Res Ther
. 2024 Sep;
15(1):301.
PMID: 39278909
Background: Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressive motoneuron degenerative disorder. There are still no drugs capable of slowing disease evolution or improving life quality of ALS...
6.
Carvalho E, Penha J, Maeda N, Abud K, Souza M, Castro C, et al.
Sci Rep
. 2024 Jul;
14(1):16612.
PMID: 39025999
Although Down syndrome (DS) is considered a risk factor for hemodynamic instabilities (mainly pulmonary hypertension-PH) following surgery for congenital cardiac communications, many DS patients do surprising well postoperatively. We prospectively...
7.
Delamain M, Cardoso A, Pericole F, da Silva Araujo S, Fogliatto L, Higashi M, et al.
Oncol Ther
. 2024 Jun;
12(3):585-598.
PMID: 38829416
Introduction: RTXM83, a biosimilar of rituximab, was approved after physicochemical, functional, non-clinical, and clinical studies demonstrated their similarity; these studies included RTXM83-AC-01-11, a multicentric double-blind international prospective pivotal study. Long-term...
8.
de Freitas F, Levy D, Reichert C, Sampaio-Silva J, Giglio P, Lage L, et al.
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38731966
Leukemias are among the most prevalent types of cancer worldwide. Bone marrow mesenchymal stem cells (MSCs) participate in the development of a suitable niche for hematopoietic stem cells, and are...
9.
Lage L, De Vita R, Alves L, Jacomassi M, Culler H, Reichert C, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672542
Background: Diffuse large B-cell lymphoma (DLBCL) especially affects the older population. Old (≥60 years) and very old age (≥80 years) DLBCL patients often present high-risk molecular alterations, lower tolerability to...
10.
Vargas J, Cecyn K, de Oliveira Marques M, Pereira J, Tobias Braga W, Hamerschlak N, et al.
EJHaem
. 2024 Feb;
5(1):147-152.
PMID: 38406522
After initiating combined antiretroviral therapy (cART), individuals with human immunodeficiency virus (HIV) may develop Hodgkin/non-Hodgkin lymphoma due to immune reconstitution inflammatory syndrome (IRIS). This retrospective cohort study evaluated the incidence,...